Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Vaccines
Wacker to produce COVID-19 vaccine for CureVac
by Alex Scott
November 28, 2020
| A version of this story appeared in
Volume 98, Issue 46
Credit: Wacker Chemie
Wacker's Amsterdam facility
Wacker Chemie is one of several European firms to secure a contract to supply ribonucleic acid for CureVac’s COVID-19 vaccine candidate, CVnCoV. Wacker has capability to produce more than 100 million doses per year of CVnCoV at its facility in Amsterdam. The vaccine, which CureVac began developing in January, is in Phase 2 trials.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X